Arusha Oloumi

Scientific Advisor for Mesothelioma for Bristol Myers Squibb

Dr. Oloumi recieved her PhD in Cancer Biology in 2002 from the Department of Pathology and Laboratory Medicine at the University of British Columbia for her work on Cell-cell contact induced resistance to etoposide. She the joined BC Cancer as a Postdoctoral Fellow and Research Associate. In 2010 she was made Staff Scientist and Project Manager for the Aparicio Lab. Since leaving the Aparicio Lab in 2015, Dr. Oloumi has worked at the Janssen Pharmaceurical Companies of Johnson & Johnson and Bristol Myers Squibb. She is currently the Scientific Advisor for Mesothelioma for Bristol Myers Squibb.


CDK12 regulates alternative last exon mRNA splicing and promotes breast cancer cell invasion.

CLK-dependent exon recognition and conjoined gene formation revealed with a novel small molecule inhibitor.

The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes.

Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution.

Integrative analysis of genome-wide loss of heterozygosity and monoallelic expression at nucleotide resolution reveals disrupted pathways in triple-negative breast cancer.

The clonal and mutational evolution spectrum of primary triple-negative breast cancers.

JointSNVMix: a probabilistic model for accurate detection of somatic mutations in normal/tumour paired next-generation sequencing data.

Feature-based classifiers for somatic mutation detection in tumour-normal paired sequencing data.

ARID1A mutations in endometriosis-associated ovarian carcinomas.

Cooperative signaling between Wnt1 and integrin-linked kinase induces accelerated breast tumor development.